Top

Published in:

01-04-2010 | SHORT REPORT

Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed Malignant Haemangioperyctoma /Solitary Fibrous Tumour

Authors: Julien Domont, Christophe Massard, Nathalie Lassau, Jean-Pierre Armand, Axel Le Cesne, Jean-Charles Soria

Published in: Investigational New Drugs | Issue 2/2010

Excerpt

Soft tissue sarcomas are a highly heterogeneous group of tumors. Recently, different molecular abnormalities were identified and in some cases corresponding molecular targeted therapies led to significant clinical benefits. …

Gengler C, Guillou L (2006) Solitary fibrous tumour and haemangiopericytoma: evolution of a concept. Histopathology 48(1):63–74. doi:10.1111/j.1365-2559.2005.02290.x ReviewCrossRefPubMed

Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Choi H, Benjamin RS, Araujo DM (2008) Combination therapy with temozolomide and bevacizumab in the treatment of hemangiopericytoma/malignant solitary fibrous tumor. J Clin Oncol 26:(May 20 suppl; abstr 10512)

Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24(1):25–35. doi:10.1200/JCO.2005.02.2194 CrossRefPubMed

DuBois S, Demetri G (2007) Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 109(5):813–819. doi:10.1002/cncr.22455 ReviewCrossRefPubMed

Balasubramanian L, Evens AM (2006) Targeting angiogenesis for the treatment of sarcoma. Curr Opin Oncol 18(4):354–359. doi:10.1097/01.cco.0000228741.64541.ca ReviewCrossRefPubMed

Title: Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed Malignant Haemangioperyctoma /Solitary Fibrous Tumour
Authors: Julien Domont
Christophe Massard
Nathalie Lassau
Jean-Pierre Armand
Axel Le Cesne
Jean-Charles Soria
Publication date: 01-04-2010
Publisher: Springer US
Published in: Investigational New Drugs / Issue 2/2010
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-009-9249-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2010

Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics

The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines

A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis

The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug

N-4-iodophenyl-N′-2-chloroethylurea, a novel potential anticancer agent with colon-specific accumulation: radioiodination and comparative in vivo biodistribution profiles

Comparison of the cytotoxic effect of lapachol, α-lapachone and pentacyclic 1,4-naphthoquinones on human leukemic cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer